Reposted by @sessicabelon.bsky.social
GOOD NEWS! Phase I clinical trial results out of Johns Hopkins show a first-of-its-kind vaccine designed to target common KRAS mutations was safe AND stimulated KRAS-specific T-cell responses in 90% of study participants who were at HIGH risk of developing pancreatic ductal adenocarcinoma (PDAC).
insideprecisionmedicine.com
Pancreatic Cancer Vaccine Triggers Immune Response Before Tumors Develop
Phase I results show early promise for a vaccine designed to prevent pancreatic cancer in people at high risk of developing the disease.
